Glucose Promotes the Production of Interleukine-1beta and Cyclooxygenase-2 in Mesangial Cells Via Enhanced (Pro)renin Receptor Expression
Overview
Authors
Affiliations
(Pro)renin receptor (PRR) is present in renal glomeruli, and its expression is up-regulated in diabetes. Similarly, renal inflammation is increased in the presence of hyperglycemia. The linkage between PRR and renal inflammation is not well established. We hypothesized that glucose-induced up-regulation of PRR leads to increased production of the proinflammatory factors IL-1beta and cyclooxygenase-2 (COX-2). Studies were conducted in rat mesangial cells (RMCs) exposed to 30 mm D-glucose for 2 wk followed by PRR small interfering RNA knockdown, IL-1 receptor blockade with IL-1 receptor antagonist or angiotensin II type 1 receptor blockade with valsartan. The results showed that D-glucose treatment up-regulates prorenin, renin, angiotensin II, PRR, IL-1beta, and COX-2 mRNA and protein expression and increases phosphorylation of ERK1/2, c-Jun N-terminal kinase, c-Jun, and nuclear factor-kappaB (NF-kappaB) p65 (serine 276,468 and 536), respectively. PRR small interfering RNA attenuated PRR, IL-1beta, and COX-2 mRNA and protein expressions and significantly decreased angiotensin II production and phosphorylation of ERK1/2 and NF-kappaB p65 associated with high glucose exposure. Similarly, IL-1 receptor antagonist significantly reduced COX-2 mRNA and protein expression induced by high glucose. COX-2 inhibition reduced high-glucose-induced PRR expression. We conclude that glucose induces the up-regulation of PRR and its ligands prorenin and renin, leading to increased IL-1beta and COX-2 production via the angiotensin II-dependent pathway. It is also possible that PRR could enhance the production of these inflammatory cytokines through direct stimulation of ERK1/2-NF-kappaB signaling cascade.
Larenas P, Cardenas P, Aguirre-Delgadillo M, Moris C, Casarini D, Vallotton Z Biol Res. 2024; 57(1):81.
PMID: 39506854 PMC: 11542404. DOI: 10.1186/s40659-024-00560-8.
Iacobini C, Vitale M, Sentinelli F, Haxhi J, Pugliese G, Menini S Int J Mol Sci. 2024; 25(4).
PMID: 38396894 PMC: 10888662. DOI: 10.3390/ijms25042217.
Wang X, Liu M, Li X, Zhang M, Xu F, Liu H Sci Rep. 2024; 14(1):625.
PMID: 38182871 PMC: 10770388. DOI: 10.1038/s41598-024-51150-3.
Targeting the (pro)renin receptor in cancers: from signaling to pathophysiological effects.
Ouyang X, Xu C J Cancer Res Clin Oncol. 2022; 149(6):2595-2605.
PMID: 36153775 DOI: 10.1007/s00432-022-04373-8.
Lara L, Gonzalez A, Hennrikus M, Prieto M Curr Hypertens Rev. 2022; 18(2):91-100.
PMID: 35170417 PMC: 10132771. DOI: 10.2174/1573402118666220216105357.